Loading company
Disc Medicine, Inc.
IRON · Nasdaq · ·
Next earnings: November 5, 2026
$65.89+1.5%Sep 29 close
- 1M
- -17.7%
- 6M
- +8.4%
- 1Y
- -0.3%
- 5Y
- +46.1%
IRON · Nasdaq · ·
Next earnings: November 5, 2026
$65.89+1.5%Sep 29 close
Disc Medicine, Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$59.5M | -$55.2M | -7.76% |
| Profit per share | -$1.54 | -$1.58 | +2.53% |
| Free Cash Flow | -$44.2M | -$48M | +7.83% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Disc Medicine, Inc. has no earnings call transcript available.
“The anticipated readout of the Phase 3 APOLLO trial of bitopertin in EPP in Q4 marks a significant milestone. We have continued driving forward on this program over the past quarter with the launch of our EAP,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Disc Medicine, Inc.’s Item 2.02 8-K filed July 30, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.